Continuous Biofilm Disrupting Materials

连续生物膜破坏材料

基本信息

批准号：
7612392
负责人：
SHANTHA s SARANGAPANI
金额：
$ 12.4万
依托单位：
INNOVATIVE CHEMICAL/ENVIRONMENTAL TECH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-02-15 至 2010-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7612392
关键词：
2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole Acids Address Adherence Adhesions Adopted Adverse reactions Antibiotics Area Binding Biological Biological Assay Blood Vessels Body Fluids Butadiene Calcium Calcium Binding Catheters Chelating Agents Chlorhexidine Citrates Citric Acid Clinical Color Complex Deposition Development Devices Diffusion Drug Delivery Systems Drug Formulations Drug resistance Economics Edetic Acid Elderly Environment Event Excipients Filler Film Fluorescence Microscopy Foundations Funding Gastrostomy Goals Growth Health Insurance Health care facility Hospitals Hybrids In Vitro Industry Infection Insurance Ions Kinetics Laboratories Ligands Liquid substance Local Anti-Infective Agents Magnesium Marketing Medical Medical Device Methods Microbial Biofilms Molds Morphology Multi-Drug Resistance Nature Nosocomial Infections Organism Patients Permeability Pharmaceutical Preparations Phase Phase I Clinical Trials Plant Resins Plastics Play Polyethylene Glycols Polymer Chemistry Polymers Polysaccharides Polyurethanes Population Powder dose form Preparation Process Property Proteins Provider Publishing Reporting Research Resistance Role Sampling Serum Silicones Silver Solubility Solutions Stents Sulfadiazine Surface Synthetic Rubber System Technology Temperature Therapeutic Tube Universities Washington Water Weight Work aged antimicrobial bacterial resistance base conditioning controlled release cost crosslink experience hydrophilicity inhibitor/antagonist levan melting microbial microbicide nano nanosized novel pathogen polycarbonate pressure prevent public health relevance success trend

项目摘要

DESCRIPTION (provided by applicant): An increasing pressure to resist the hospital-acquired infection rates by insurance providers is expected to play a crucial role in the growth of the infection resistant treatments and materials according to Frost & Sullivan research. Muti-drug resistant bacterial biofilms pose a constant threat to medical devices and recently the health insurance companies are showing a strong trend of non-coverage of hospital related infection episodes. Technologies such as coating of the catheters or devices with antibiotics or antiseptics like as nano silver, silver sulfadiazine and/or chlorhexidine, antibiotics have been commercialized with limited success due to rapid release rates resulting in depletion of the eluting antimicrobials. Most medical devices such as vascular and other catheters and non-vascular stents are made of thermoplastic medical grade polymers such as polyurethanes. Additives such as colors, inert fillers etc are compounded with a resin under melt conditions, pelletized and then used for extrusion. We propose the idea of incorporating on lab scale, a thermally stable, antimicrobial, biofilm inhibiting formula by compounding it into a medical grade polyurethane followed by extrusion. We will develop compositions with an ability to release active material for up to 30days in sustained manner at effective levels. Such materials could be further optimized to show ultra slow release over several months. (6months is the ultimate target) During the Phase I, for the proof of our concept, we will synthesize and develop formulations that function as antimicrobial inhibitors and form unique silver species that are more soluble and stable in biological media. These will be used as additives at various defined levels into to a medical grade polyurethane matrix using a water insoluble nanosize natural carrier, compounded and processed as flat plastic samples for the Phase I study. We hope to demonstrate a highly controlled long term release from such matrices that provide the surface with biofilm resistance against clinical pathogens in a biological medium with sera. We will create materials with precise concentrations of the active materials and screen them for elution profile, bacterial attachment kinetics and biofilm abrogation. PUBLIC HEALTH RELEVANCE Recent analysis from Frost & Sullivan found that the U.S. antimicrobial treatment markets earned revenues of $175.4M in 2005 with estimates to reach $558.7M by 2012. The market expects to grow with the increasing need to address microbial growth in end-application markets like health care facilities.

描述（由申请人提供）：根据Frost＆Sullivan Research，预计保险提供商抵抗医院获得的感染率的压力越来越大，在抗感染疗法和材料的生长中起着至关重要的作用。抗Muti-prug的细菌生物膜对医疗设备构成不断威胁，最近，健康保险公司表现出强烈的不覆盖医院相关感染发作的趋势。诸如涂层或具有抗生素或抗菌药的设备之类的技术，例如纳米银，磺胺二嗪银和/或洗涤酰胺，由于释放速度的快速释放速率，抗生素已被商业化，导致释放速度的迅速释放，导致了洗脱抗菌药物的消耗。大多数医疗设备，例如血管，其他导管以及非血管支架都是由热塑性医学级聚合物（例如聚氨酯）制成的。添加剂（例如颜色，惰性填充剂等）在熔体条件下加上树脂，重新构成树脂，然后用于挤出。我们提出了在实验室量表上合并的想法，该想法是一种热稳定，抗菌，生物膜抑制公式，将其通过将其复合到医学级聚氨酯中，然后挤出。我们将开发具有有效水平的持续方式以持续方式释放活性材料的能力。可以进一步优化此类材料，以显示几个月内超缓慢的释放。（6个月是最终的目标）在第一阶段，为了证明我们的概念，我们将合成和开发作为抗菌抑制剂的配方，并形成在生物学培养基中更易溶和稳定的独特银物种。这些将使用不溶性纳米式天然载体，将其用作各种定义水平的添加剂到医学级聚氨酯基质，并作为I期研究中的平坦塑料样品进行复合和加工。我们希望能够证明从此类矩阵中的高度控制的长期释放，这些矩阵在具有血清的生物学培养基中为临床病原体提供了对临床病原体的抗性。我们将创建具有精确浓度的活性材料的材料，并将其筛选为洗脱剖面，细菌附着动力学和生物膜废除。公共卫生相关性最近来自Frost＆Sullivan的分析发现，美国抗菌治疗市场在2005年的收入为1.754亿美元，估计到2012年到2012年达到5.587亿美元。该市场预计，随着医疗保健机构等最终应用市场中微生物增长的需求，该市场预计会增长。